{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:43:33Z","timestamp":1788327813169,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advanced salivary gland mucoepidermoid carcinoma (MEC) is a relentless cancer that exhibits resistance to conventional chemotherapy. As such, treatment for patients with advanced MEC is tipically radical surgery and radiotherapy. Facial disfigurement and poor quality of life are frequent treatment challenges, and many patients succumb to loco-regional recurrence and\/or metastasis. We know that cancer stem-like cells (CSC) drive MEC tumorigenesis. The current study tests the hypothesis that MEC CSC are sensitive to therapeutic inhibition of mTOR. Here, we report a correlation between the long-term clinical outcomes of 17 MEC patients and the intratumoral expression of p-mTOR (<jats:italic>p<\/jats:italic>\u2009=\u20090.00294) and p-S6K1 (<jats:italic>p<\/jats:italic>\u2009=\u20090.00357). In vitro, we observed that MEC CSC exhibit constitutive activation of the mTOR signaling pathway (i.e., mTOR, AKT, and S6K1), unveiling a potential strategy for targeted ablation of these cells. Using a panel of inhibitors of the mTOR pathway, i.e., rapamycin and temsirolimus (mTOR inhibitors), buparlisib and LY294002 (AKT inhibitors), and PF4708671 (S6K1 inhibitor), we observed consistently dose-dependent decrease in the fraction of CSC, as well as inhibition of secondary sphere formation and self-renewal in three human MEC cell lines (UM-HMC-1,-3A,-3B). Notably, therapeutic inhibition of mTOR with rapamycin or temsirolimus induced preferential apoptosis of CSC, when compared to bulk tumor cells. In contrast, conventional chemotherapeutic drugs (cisplatin, paclitaxel) induced preferential apoptosis of bulk tumor cells and accumulation of CSC. In vivo, therapeutic inhibition of mTOR with temsirolimus caused ablation of CSC and downregulation of Bmi-1 expression (major inducer of stem cell self-renewal) in MEC xenografts. Transplantation of MEC cells genetically silenced for mTOR into immunodeficient mice corroborated the results obtained with temsirolimus. Collectively, these data demonstrated that mTOR signaling is required for CSC survival, and unveiled the therapeutic potential of targeting the mTOR pathway for elimination of highly tumorigenic cancer stem-like cells in salivary gland mucoepidermoid carcinoma.<\/jats:p>","DOI":"10.1038\/s41419-021-03391-7","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T09:03:23Z","timestamp":1611219803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Survival of salivary gland cancer stem cells requires mTOR signaling"],"prefix":"10.1038","volume":"12","author":[{"given":"Nathalia P.","family":"Andrade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy A.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaocheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mantesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Guimara\u0113s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Altemani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda V.","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio D.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4056-0235","authenticated-orcid":false,"given":"Jacques E.","family":"N\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"3391_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1034\/j.1601-0825.2002.02870.x","volume":"8","author":"PM Speight","year":"2002","unstructured":"Speight, P. M. & Barrett, A. W. Salivary gland tumours. Oral Dis. 8, 229\u2013240 (2002).","journal-title":"Oral Dis."},{"key":"3391_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00405-014-3053-z","volume":"272","author":"A Coca-Pelaz","year":"2015","unstructured":"Coca-Pelaz, A. et al. Salivary mucoepidermoid carcinoma revisited. Eur. Arch. Otorhinolaryngol. 272, 799\u2013819 (2015).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"3391_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/hed.23249","volume":"36","author":"V Vander Poorten","year":"2014","unstructured":"Vander Poorten, V. et al. Recent trends in the management of minor salivary gland carcinoma. Head Neck 36, 444\u2013455 (2014).","journal-title":"Head Neck"},{"key":"3391_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","volume":"66","author":"S Alfieri","year":"2017","unstructured":"Alfieri, S. et al. Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol. 66, 58\u201363 (2017).","journal-title":"Oral Oncol."},{"key":"3391_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.oraloncology.2017.02.018","volume":"68","author":"G Keller","year":"2017","unstructured":"Keller, G. et al. New concepts of personalized therapy in salivary gland carcinomas. Oral Oncol. 68, 103\u2013113 (2017).","journal-title":"Oral Oncol."},{"key":"3391_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.copbio.2007.10.007","volume":"18","author":"LE Ailles","year":"2007","unstructured":"Ailles, L. E. & Weissman, I. L. Cancer stem cells in solid tumors. Curr. Opin. Biotechnol. 18, 460\u2013466 (2007).","journal-title":"Curr. Opin. Biotechnol."},{"key":"3391_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oraloncology.2011.10.004","volume":"48","author":"Z Zhang","year":"2012","unstructured":"Zhang, Z., Filho, M. S. & N\u00f6r, J. E. The biology of head and neck cancer stem cells. Oral Oncol. 48, 1\u20139 (2012).","journal-title":"Oral Oncol."},{"key":"3391_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nature07733","volume":"458","author":"M Diehn","year":"2009","unstructured":"Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780\u2013783 (2009).","journal-title":"Nature"},{"key":"3391_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.oraloncology.2013.05.013","volume":"49","author":"A Adams","year":"2013","unstructured":"Adams, A., Warner, K. & N\u00f6r, J. E. Salivary gland cancer stem cells. Oral Oncol. 49, 845\u2013853 (2013).","journal-title":"Oral Oncol."},{"key":"3391_CR10","doi-asserted-by":"publisher","first-page":"42447","DOI":"10.18632\/oncotarget.9884","volume":"7","author":"DM Guimaraes","year":"2016","unstructured":"Guimaraes, D. M. et al. Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells. Oncotarget 7, 42447\u201342460 (2016).","journal-title":"Oncotarget"},{"key":"3391_CR11","doi-asserted-by":"publisher","first-page":"26633","DOI":"10.18632\/oncotarget.5782","volume":"6","author":"A Adams","year":"2015","unstructured":"Adams, A. et al. ALDH\/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget 6, 26633\u201326650 (2015).","journal-title":"Oncotarget"},{"key":"3391_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/jnci\/djw189","volume":"109","author":"SB Keysar","year":"2016","unstructured":"Keysar, S. B. et al. Regulation of head and neck squamous cancer stem cells by PI3K and SOX2. J. Natl Cancer Inst. 109, 189 (2016).","journal-title":"J. Natl Cancer Inst."},{"key":"3391_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3346\/jkms.2016.31.3.360","volume":"31","author":"MJ Kim","year":"2016","unstructured":"Kim, M. J. et al. Dual-blocking of PI3K and mTOR improves chemotherapeutic effects on SW620 human colorectal cancer stem cells by inducing differentiation. J. Korean Med. Sci. 31, 360\u2013370 (2016).","journal-title":"J. Korean Med. Sci."},{"key":"3391_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","volume":"67","author":"IA Mayer","year":"2016","unstructured":"Mayer, I. A. & Arteaga, C. L. The PI3K\/AKT pathway as a target for cancer treatment. Annu. Ver. Med. 67, 11\u201328 (2016).","journal-title":"Annu. Ver. Med."},{"key":"3391_CR15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/odi.12504","volume":"22","author":"S Diamanti","year":"2016","unstructured":"Diamanti, S., Nikitakis, N., Rassidakis, G., Doulis, I. & Sklavounou, A. Immunohistochemical evaluation of the mTOR pathway in intra-oral minor salivary gland neoplasms. Oral Dis. 22, 620\u2013629 (2016).","journal-title":"Oral Dis."},{"key":"3391_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jop.12064","volume":"42","author":"TS Clauditz","year":"2013","unstructured":"Clauditz, T. S. et al. Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target? J. Oral Pathol. Med. 42, 769\u2013773 (2013).","journal-title":"J. Oral Pathol. Med."},{"key":"3391_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.oraloncology.2012.02.021","volume":"48","author":"T Ettl","year":"2012","unstructured":"Ettl, T. et al. The PI3K\/AKT\/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol. 48, 822\u2013830 (2012).","journal-title":"Oral Oncol."},{"key":"3391_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrc1974","volume":"6","author":"DM Sabatini","year":"2006","unstructured":"Sabatini, D. M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6, 729\u2013734 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"3391_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jbior.2016.12.001","volume":"64","author":"M Jhanwar-Uniyal","year":"2017","unstructured":"Jhanwar-Uniyal, M. et al. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects. Adv. Biol. Regul. 64, 39\u201348 (2017).","journal-title":"Adv. Biol. Regul."},{"key":"3391_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin, D. A. & Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell 12, 9\u201322 (2007).","journal-title":"Cancer Cell"},{"key":"3391_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"DH Kim","year":"2002","unstructured":"Kim, D. H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163\u2013175 (2002).","journal-title":"Cell"},{"key":"3391_CR22","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"DD Sarbassov","year":"2004","unstructured":"Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296\u20131302 (2004).","journal-title":"Curr. Biol."},{"key":"3391_CR23","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/ncb1183","volume":"6","author":"E Jacinto","year":"2004","unstructured":"Jacinto, E. et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122\u20131128 (2004).","journal-title":"Nat. Cell Biol."},{"key":"3391_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.molmed.2005.06.007","volume":"11","author":"DA Guertin","year":"2005","unstructured":"Guertin, D. A. & Sabatini, D. M. An expanding role for mTOR in cancer. Trends Mol. Med. 11, 353\u2013361 (2005).","journal-title":"Trends Mol. Med."},{"key":"3391_CR25","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","volume":"25","author":"JB Easton","year":"2006","unstructured":"Easton, J. B. & Houghton, P. J. mTOR and cancer therapy. Oncogene 25, 6436\u20136446 (2006).","journal-title":"Oncogene"},{"key":"3391_CR26","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms13021886","volume":"13","author":"H Populo","year":"2012","unstructured":"Populo, H., Lopes, J. M. & Soares, P. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 13, 1886\u20131918 (2012).","journal-title":"Int. J. Mol. Sci."},{"key":"3391_CR27","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2217\/fon.15.70","volume":"11","author":"Z Huang","year":"2015","unstructured":"Huang, Z. et al. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Future Oncol. 11, 1687\u20131699 (2015).","journal-title":"Future Oncol."},{"key":"3391_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/1078-0432.CCR-05-1654","volume":"12","author":"CA Granville","year":"2006","unstructured":"Granville, C. A., Memmott, R. M., Gills, J. J. & Dennis, P. A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase\/AKT\/mammalian target of rapamycin pathway. Clin. Cancer Res. 12, 679\u2013689 (2006).","journal-title":"Clin. Cancer Res."},{"key":"3391_CR29","doi-asserted-by":"publisher","first-page":"9969","DOI":"10.1158\/0008-5472.CAN-10-1712","volume":"70","author":"S Krishnamurthy","year":"2010","unstructured":"Krishnamurthy, S. et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res. 70, 9969\u20139978 (2010).","journal-title":"Cancer Res."},{"key":"3391_CR30","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res. 66, 1500\u20131508 (2006).","journal-title":"Cancer Res."},{"key":"3391_CR31","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.prp.2014.03.008","volume":"210","author":"W Liu","year":"2014","unstructured":"Liu, W. et al. Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: in vitro and in vivo. Pathol. Res. Pract. 210, 764\u2013769 (2014).","journal-title":"Pathol. Res. Pract."},{"key":"3391_CR32","doi-asserted-by":"publisher","first-page":"50476","DOI":"10.18632\/oncotarget.9919","volume":"8","author":"S Chen","year":"2017","unstructured":"Chen, S. et al. Inhibition of PI3K\/AKT\/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis. Oncotarget 8, 50476\u201350488 (2017).","journal-title":"Oncotarget"},{"key":"3391_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature20578","volume":"540","author":"A Bulut-Karslioglu","year":"2016","unstructured":"Bulut-Karslioglu, A. et al. Inhibition of mTOR induces a paused pluripotent state. Nature 540, 119\u2013123 (2016).","journal-title":"Nature"},{"key":"3391_CR34","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1242\/dev.137075","volume":"143","author":"JS Yu","year":"2016","unstructured":"Yu, J. S. & Cui, W. Proliferation, survival and metabolism: the role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination. Development 143, 3050\u20133060 (2016).","journal-title":"Development"},{"key":"3391_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1042\/BJ20101024","volume":"431","author":"LR Pearce","year":"2010","unstructured":"Pearce, L. R. et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem. J. 431, 245\u2013255 (2010).","journal-title":"Biochem. J."},{"key":"3391_CR36","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1172\/JCI84565","volume":"126","author":"J Ghosh","year":"2016","unstructured":"Ghosh, J. et al. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance. J. Clin. Invest. 126, 2621\u20132625 (2016).","journal-title":"J. Clin. Invest."},{"key":"3391_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature03205","volume":"433","author":"JD Richter","year":"2005","unstructured":"Richter, J. D. & Sonenberg, N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433, 477\u2013480 (2005).","journal-title":"Nature"},{"key":"3391_CR38","doi-asserted-by":"publisher","first-page":"22822","DOI":"10.18632\/oncotarget.4477","volume":"6","author":"D Mochizuki","year":"2015","unstructured":"Mochizuki, D. et al. Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget 6, 22822\u201322835 (2015).","journal-title":"Oncotarget"},{"key":"3391_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1593\/neo.131744","volume":"16","author":"C N\u00f6r","year":"2014","unstructured":"N\u00f6r, C. et al. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia 16, 137\u2013146 (2014).","journal-title":"Neoplasia"},{"key":"3391_CR40","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/bcp.12844","volume":"82","author":"MG Francipane","year":"2016","unstructured":"Francipane, M. G. & Lagasse, E. Therapeutic potential of mTOR inhibitors for targeting cancer stem cells. Br. J. Clin. Pharmacol. 82, 1180\u20131188 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3391_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.cdd.4400978","volume":"9","author":"M Castedo","year":"2002","unstructured":"Castedo, M., Ferri, K. F. & Kroemer, G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ. 9, 99\u2013100 (2002).","journal-title":"Cell Death Differ."},{"key":"3391_CR42","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","volume":"107","author":"DT Teachey","year":"2006","unstructured":"Teachey, D. T. et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107, 1149\u20131155 (2006).","journal-title":"Blood"},{"key":"3391_CR43","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.1158\/0008-5472.CAN-10-3192","volume":"71","author":"V Patel","year":"2011","unstructured":"Patel, V. et al. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res. 71, 7103\u20137112 (2011).","journal-title":"Cancer Res."},{"key":"3391_CR44","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","volume":"11","author":"DA Guertin","year":"2006","unstructured":"Guertin, D. A. et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to AKT-FOXO and PKCalpha, but not S6K1. Dev. Cell 11, 859\u2013871 (2006).","journal-title":"Dev. Cell"},{"key":"3391_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"21","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and AKT\/PKB. Mol. Cell 21, 159\u2013168 (2006).","journal-title":"Mol. Cell"},{"key":"3391_CR46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128\u2013135 (2002).","journal-title":"Nat. Med."},{"key":"3391_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","volume":"10","author":"TL Phung","year":"2006","unstructured":"Phung, T. L. et al. Pathological angiogenesis is induced by sustained AKT signaling and inhibited by rapamycin. Cancer Cell 10, 159\u2013170 (2006).","journal-title":"Cancer Cell"},{"key":"3391_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2012.07.025","volume":"338","author":"KE Ritchie","year":"2013","unstructured":"Ritchie, K. E. & N\u00f6r, J. E. Perivascular stem cell niche in head and neck cancer. Cancer Lett. 338, 41\u201346 (2013).","journal-title":"Cancer Lett."},{"key":"3391_CR49","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.oraloncology.2013.08.004","volume":"49","author":"KA Warner","year":"2013","unstructured":"Warner, K. A. et al. Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma. Oral Oncol. 49, 1059\u20131066 (2013).","journal-title":"Oral Oncol."},{"key":"3391_CR50","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/labinvest.3780253","volume":"81","author":"JE N\u00f6r","year":"2001","unstructured":"N\u00f6r, J. E. et al. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab. Invest. 81, 453\u2013463 (2001).","journal-title":"Lab. Invest."},{"key":"3391_CR51","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/1078-0432.CCR-16-1235","volume":"23","author":"F N\u00f6r","year":"2017","unstructured":"N\u00f6r, F. et al. Therapeutic inhibition of the MDM2-p53 interaction prevents recurrence of adenoid cystic carcinomas. Clin. Cancer Res. 23, 1036\u20131048 (2017).","journal-title":"Clin. Cancer Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03391-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03391-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03391-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:48:53Z","timestamp":1669920533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03391-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["3391"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03391-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for access to histological tissue sections was obtained through the Human Subjects Ethics Committee of the School of Dentistry, UNICAMP and University of S\u00e3o Paulo, Brazil.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"108"}}